Molbio Diagnostics Limited IPO — the disclosed details
Closed
The publicly disclosed details of the Molbio Diagnostics mainboard IPO — band, lot, offer structure, objects, risk factors and dates — restated from the RHP of August 3, 2026 and the price-band advertisement of August 6, 2026.
This issue's bidding window has closed. What follows is the record of what was disclosed while the offer was open. It is not updated after the close, and it is not a view on the company or on how the shares have traded since.
Molbio Diagnostics Limited is running a mainboard IPO on BSE and NSE, open for bidding from Monday, August 10 to Wednesday, August 12, 2026. This page restates what the company has publicly disclosed — in the Red Herring Prospectus dated August 3, 2026 and the price-band advertisement dated August 6, 2026 — and nothing more. If the vocabulary is new — DRHP, price band, buckets, allotment — read how an Indian IPO actually works first.
What institutional desks read first — the filed ratios
These are the company’s own quantitative disclosures from the “Basis for the Offer Price” chapter of the RHP dated August 3, 2026, restated as printed — this is not a valuation, and no view is offered on any of them.
| Ratio, as filed | Value |
|---|---|
| Basic EPS (₹) | FY2026: 14.77 · FY2025: 12.87 · FY2024: 9.05 · Weighted average: 13.18 |
| Diluted EPS (₹) | FY2026: 14.77 · FY2025: 12.87 · FY2024: 9.04 · Weighted average: 13.18 |
| P/E at the Floor Price | Printed as [●] — “To be computed after finalisation of the Price Band” |
| P/E at the Cap Price | Printed as [●] — same footnote; the RHP itself carries no P/E number for the company |
| Industry peer P/E | Highest 81.02 · Lowest 52.61 · Average 64.89 — the RHP’s own computation, on BSE closing prices of July 30, 2026 divided by FY2026 diluted EPS |
| Return on Net Worth (%) | FY2026: 14.55 · FY2025: 15.23 · FY2024: 12.62 · Weighted average: 14.46 |
| NAV per equity share (₹) | 101.51 as at March 31, 2026; post-Offer NAV at floor, cap and Offer Price all printed as [●], to be computed post finalisation of the Price Band |
The RHP also files sixteen KPIs in this chapter, certified by B.B. & Associates, Chartered Accountants, on August 3, 2026. The headline financial ones, as printed:
| KPI, as filed | Value |
|---|---|
| Revenue from operations (₹ million) | FY2026: 14,456.87 · FY2025: 10,204.18 · FY2024: 8,365.61 |
| EBITDA (₹ million) | FY2026: 3,282.43 · FY2025: 2,566.39 · FY2024: 1,850.93 |
| EBITDA margin (%) | FY2026: 22.56 · FY2025: 24.97 · FY2024: 22.02 |
| Profit for the year (₹ million) | FY2026: 1,641.40 · FY2025: 1,385.79 · FY2024: 835.42 |
| Return on equity (%) | FY2026: 15.59 · FY2025: 16.20 · FY2024: 13.20 |
| Return on capital employed (%) | FY2026: 17.55 · FY2025: 20.98 · FY2024: 15.80 |
The RHP names four listed companies in its peer-comparison table. Its own framing: there are “no directly comparable listed companies in India or globally”, and these four — engaged in disposable medical devices or pathology diagnostic services, not point-of-care molecular diagnostics manufacturing — are provided only for reference as its nearest listed peers. All figures are for or as at the year ended March 31, 2026, as printed:
| Listed peer | Face value (₹) | EPS basic (₹) | EPS diluted (₹) | P/E | RoNW (%) | NAV per share (₹) | Revenue from operations (₹ million) |
|---|---|---|---|---|---|---|---|
| Molbio Diagnostics Limited (own row) | 1 | 14.77 | 14.77 | [●] — to be included in the Prospectus based on the Offer Price | 14.55 | 101.51 | 14,456.87 |
| Poly Medicure Limited | 5 | 31.79 | 31.75 | 52.61 | 10.37 | 306.45 | 18,752.59 |
| Dr. Lal Pathlabs Limited | 10 | 30.24 | 30.20 | 62.20 | 20.78 | 145.00 | 27,629.11 |
| Metropolis Healthcare Limited | 2 | 9.19 | 9.19 | 63.72 | 12.56 | 72.98 | 16,458.46 |
| Vijaya Diagnostics Centre Limited | 1 | 16.81 | 16.79 | 81.02 | 18.07 | 93.02 | 8,142.02 |
What the RHP does not state: it contains no EV/EBITDA figure anywhere in this chapter — neither for the company nor in the peer table — no price-to-revenue multiple, and no P/E, post-Offer NAV or market capitalisation for the company itself, all of which are left as [●] pending finalisation of the Price Band; nothing here is computed by this site.
What the company does
Molbio Diagnostics is a point-of-care diagnostics company. It was incorporated in Goa in 2000, and its registered and corporate office is at Verna, South Goa. Its Truenat platform is a battery-operated point-of-care PCR system that can operate in resource-limited settings and deliver decentralised results within one hour. As of March 31, 2026, Truenat is patented in more than 100 countries, and the company offers molecular testing for 30 diseases — including TB, COVID, hepatitis B and C, HIV and HPV — with 43 assays.
One claim needs its sourcing stated. The RHP says Truenat is the only TB-diagnosis platform by an Indian company, and one of only two rapid molecular tests in the world endorsed by the WHO for initial diagnosis of TB and rifampicin-resistance detection. That claim is attributed to the 1Lattice Report, an industry report the RHP itself discloses was commissioned and paid for by the company.
What the money is for
The offer has two parts: the fresh issue — up to Rs 200 crore of new shares — is money that goes to the company; the offer for sale — up to 9,166,000 existing shares — is money that goes to the 17 selling shareholders, not the company. The RHP states this directly: the company will not receive any proceeds from the offer for sale.
The fresh-issue money has three stated objects:
| Object of the fresh issue | Amount, as filed |
|---|---|
| Capital expenditure on a research and development facility and Center of Excellence — to be operated by the wholly-owned subsidiary Bigtec — plus connected office space for the company, its subsidiaries and associate | Total estimated cost Rs 1,251.21 million, of which Rs 1,055.35 million from net proceeds; estimated deployment Rs 264.74 million in Fiscal 2027 and Rs 790.62 million in Fiscal 2028 |
| Capital expenditure on plant, machinery and other equipment for Goa Unit I, Goa Unit II and the Visakhapatnam Unit | — |
| General corporate purposes | — |
| Selling shareholder | Offer for sale, up to |
|---|---|
| Exxora Trading LLP (promoter selling shareholder) | 1,811,000 shares |
| Dr. Chandrasekhar Bhaskaran Nair (promoter selling shareholder; shares jointly held) | 1,221,000 shares |
| India Business Excellence Fund III (investor selling shareholder) | 1,000,000 shares |
| Fourteen other shareholders | Disclosed per-seller caps that sum exactly to the 9,166,000 total |
Separately, an addendum dated August 6, 2026 discloses that Exxora Trading LLP transferred 1,982,649 shares in pre-IPO secondary transfers on August 5, 2026 — outside the offer for sale — leaving its pre-offer holding at 44,504,951 shares (39.47%).
What the RHP flags as risks
This is the company’s own risk-factor section, paraphrased. It is disclosure, not commentary.
- Customer concentration. Revenue from Indian central and state governments and international aid agencies was 84.56%, 87.83% and 91.60% of revenue from contracts with customers (sale of products — finished goods) in Fiscals 2026, 2025 and 2024 respectively. The Indian central government alone contributed Rs 7,906.52 million — 56.52% — in Fiscal 2026. The RHP says loss of these customers, policy changes or a decline in their demand could adversely affect the business.
- Product concentration. TB test kits were 70.20%, 69.11% and 62.40% of that same revenue line in Fiscals 2026, 2025 and 2024 respectively. A decline in demand for TB test kits could adversely affect the business.
- R&D execution. R&D runs through the wholly-owned subsidiary Bigtec Private Limited. Developing new tests takes substantial time and resources, and depends on demonstrating accuracy and usability and on obtaining regulatory clearances and approvals.
- Audit-report matters. The statutory auditors’ reports on the consolidated financial statements for Fiscals 2026, 2025 and 2024 include emphasis-of-matter paragraphs, modifications for certain matters and certain qualifications under Companies Act reporting requirements (CARO 2020 and Rule 11(g)). The report on internal financial controls for Fiscal 2024 contains a disclaimer of opinion.
- Loss-making subsidiaries. Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC have incurred losses in the past and may incur losses in the future. The company on a consolidated basis, and certain subsidiaries, have had negative operating cash flows in the past.
- Leasehold premises. The manufacturing facilities, the R&D unit and the registered and corporate office sit on leasehold land, not owned land. Losing or failing to renew these leaseholds could adversely affect operations.
The numbers as filed
| Item | As filed |
|---|---|
| Issue size | Up to 11,772,311 shares aggregating Rs 9,039.49 million at the floor, or up to 11,646,246 shares aggregating Rs 9,396.96 million at the cap — approximately Rs 904–940 crore |
| Fresh issue | Up to Rs 2,000.00 million (2,606,311 shares at the floor / 2,480,246 at the cap) |
| Offer for sale | Up to 9,166,000 shares |
| Price band | Rs 768 to Rs 807 per share — the floor and cap are 768 and 807 times face value |
| Face value | Rs 1 |
| Employee reservation | Up to Rs 15.00 million, with a disclosed discount of Rs 76.00 per share for eligible employees bidding in it |
| Lot size | 18 shares, and multiples of 18 thereafter |
| Minimum investment | Rs 13,824 at the floor (18 × Rs 768); Rs 14,526 at the cap (18 × Rs 807) |
| Post-offer market capitalisation, per the advertisement’s table | Rs 88,601.13 million at the floor; Rs 92,998.68 million at the cap |
The RHP leaves the price fields blank; the band was published in the price-band advertisement dated August 6, 2026. The minimum-investment figures are arithmetic from the disclosed band and lot; they are not printed as a line item in the RHP or the advertisement.
Financials, from the restated consolidated financial information (Rs million):
| Fiscal year | Revenue from operations | Restated profit for the year |
|---|---|---|
| Fiscal 2026 | 14,456.87 | 1,641.40 |
| Fiscal 2025 | 10,204.18 | 1,385.79 |
| Fiscal 2024 | 8,365.61 | 835.42 |
Who can actually sell on listing day
On listing day, most of Molbio’s share register is not allowed to trade. A lock-in is not a forecast of anything — it is a restriction on selling; it says who may trade, not what the price will do.
Here is what this RHP itself locks up. All periods run from the date of Allotment:
| Who | Locked for, per this RHP |
|---|---|
| Promoter minimum contribution — 20% of the fully diluted post-Offer capital (about 23.05 million shares at the cap’s post-Offer count), under Regulations 14 and 16 (RHP p.112) | Three years |
| Promoter holding above that 20% (RHP p.112) | One year |
| All other pre-IPO shares, under Regulation 17 (RHP p.113), except shares sold in the Offer for Sale | Six months |
| Anchor investors — 50% of anchor shares (RHP p.114) | 90 days |
| Anchor investors — the other 50% (RHP p.114) | 30 days |
The count at the Rs 807 cap:
| Step | Shares | % of post-issue capital |
|---|---|---|
| Fresh issue | 2,480,246 | 2.15% |
| Offer for Sale | 9,166,000 | 7.95% |
| Total offer | 11,646,246 | 10.11% |
| Less: anchor allotment, locked 30/90 days | −3,487,717 | −3.03% |
| = Sellable on listing day | 8,158,529 | 7.08% |
| Locked or not offered — the rest of the register | 107,081,467 | 92.92% |
| Post-issue capital | 115,239,996 | 100.00% |
| Memo: of that locked block, under an explicit lock-in | 93,804,717 | 81.40% |
| Memo: of that locked block, exempt from the six-month lock — India Business Excellence Fund III, a SEBI-registered Category II AIF | 13,276,750 | 11.52% |
The anchor book is done — Rs 281.46 crore at Rs 807 across 33 investors, finalised on August 7, 2026 and filed with the BSE, as reported by BusinessToday and Outlook Business.
One timing note: anchor locks run from Allotment (expected around August 13), so the 30-day lock ends around mid-September 2026 and the 90-day lock around mid-November 2026 — they do not run from the listing date.
These figures come from the RHP’s capital-structure disclosures (pages 76, 101, 112-114) and the anchor allocation list reported from the exchange filing, as of 12 August 2026.
Dates and mechanics
| Event | Date |
|---|---|
| Anchor investor bidding | Friday, August 7, 2026 |
| Offer opens | Monday, August 10, 2026 |
| Offer closes — UPI mandates end at 5:00 p.m. on the closing date | Wednesday, August 12, 2026 |
| Basis of allotment | On or about Thursday, August 13, 2026 |
| Demat credit and refunds/unblocking | On or about Friday, August 14, 2026 |
| Commencement of trading, on BSE and NSE | On or about Monday, August 17, 2026 |
Every date after the close is indicative — the RHP says “on or about” throughout.
The issue is a mainboard book-built offer under Regulation 6(1) of the SEBI ICDR Regulations; BSE is the designated stock exchange.
The book running lead managers are Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors — the RHP notes that Motilal Oswal Investment Advisors is involved only in marketing the offer, because a selling shareholder, India Business Excellence Fund III, is its associate. The registrar is KFin Technologies Limited, Hyderabad.
Information as of 10 Aug 2026, with the anchor and float figures updated 12 Aug 2026, taken from the offer documents and pages linked below. This is not an IPO review and no subscribe/avoid rating is given. Figures move through the issue lifecycle — check the filed documents before acting on any of them. Grey-market premium is an unofficial, unregulated price with no exchange record, and is not referenced here as information. Where the standing notice below refers to hypothetical figures, that covers the illustrative worked examples used in the options posts on this site — every number on this page is reproduced from the filed documents cited above.
This post is for educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security or derivative contract. The author is not a SEBI-registered Research Analyst or Investment Adviser. Futures and options trading carries a high risk of loss and is not suitable for every investor — you can lose your entire premium, and more when selling naked. All figures and examples in this post, including the rupee premiums and price levels, are hypothetical and used only to illustrate the framework; they are not predictions, return promises, performance claims, or a recommendation to trade any specific instrument. Lot sizes and premiums change over time — always check current exchange data before trading. Please consult a SEBI-registered investment adviser before making any investment decisions.
Sources
- Red Herring Prospectus dated August 3, 2026 — company website (full 575-page PDF fetched, text-extracted and sha256-hashed this session: 528AB05602479BC5DB29F305CD76256EC48702A9550CF6EBD9C8F2D0A227C9D2) →
- Same RHP hosted by BRLM IIFL Capital Services (re-fetched this session; sha256 identical: 528AB05602479BC5DB29F305CD76256EC48702A9550CF6EBD9C8F2D0A227C9D2) →
- Price-band advertisement + Notice to Investors (Addendum to RHP/Abridged Prospectus), signed August 6, 2026 — company website (3-page PDF fetched and text-extracted this session) →
- Company investor-relations page (document index) →
- SEBI filings page — Molbio Diagnostics Limited DRHP (regulator-hosted corroboration of the filing lineage) →
- Company newsroom announcement of the IPO filing (DRHP-era; superseded figures) →
- BusinessToday, Aug 10, 2026 — anchor allocation: 34,87,717 shares at Rs 807 = Rs 281.46 crore, 33 investors →
- Outlook Business, Aug 8, 2026 — anchor allocation filed on BSE late Friday Aug 7; Rs 281.5 cr, 33 anchors →
Common questions
How does IPO allotment work?
Applications are matched against the minimum lot size within each investor category (retail, HNI, QIB). In the retail category every applicant is first considered for one minimum lot: when the retail portion has enough shares to give every retail applicant one lot, everyone gets at least one and the surplus goes proportionately to those who bid more. Only when there aren't enough shares for one lot each is a computerised draw of lots used to pick who gets that single lot — and then each successful applicant gets exactly one lot, however many they bid for. It is never first-come-first-served, so applying early doesn't improve the odds.
What does the anchor investor lock-in mean?
Anchor investors (institutions allotted shares a day before the issue opens) are locked in and can't sell for a fixed period — and the clock runs from the date of Allotment, not from listing. Under the SEBI ICDR Regulations, 50% of the anchor shares are locked for 90 days from Allotment and the remaining 50% for 30 days from Allotment. It restricts anchors only; it says nothing about how retail-held shares will trade.
When do I get my money back if I'm not allotted?
Under ASBA, your bank only blocks the funds in your account — it's never debited until allotment. If you get no shares (or only a partial allotment), the block is released without any separate refund step: SEBI requires your bank (the SCSB) to complete the unblock by the close of banking hours on the working day after the basis of allotment is finalised — under the T+3 timeline, the day before the shares list. If it takes longer than that, SEBI's compensation policy provides ₹100 per day or 15% per annum of the application amount, whichever is higher — but it is complaint-triggered, so you have to raise it with your bank or the issue's lead manager to claim it.
What is ASBA / the UPI mandate?
ASBA (Application Supported by Blocked Amount) blocks the bid amount in your bank account instead of debiting it upfront. Retail investors bidding through UPI approve a mandate request in their UPI app, which blocks the funds — the money leaves your account only if shares are actually allotted.
The rest of the site
This page is a record of what was filed and published, and it stops there. The rest of the site is about the part that comes after you own something — how much of it to own, how to write the decision down, and how to grade it later.
Other issue pages from the same window
- LEAP India Limited · 7 Aug 2026 – 11 Aug 2026
- Technocraft Ventures Limited · 7 Aug 2026 – 11 Aug 2026
- Dhoot Transmission Limited · 10 Aug 2026 – 12 Aug 2026
- Milky Mist Dairy Food Limited · 11 Aug 2026 – 13 Aug 2026
Everything on this site is free.
Every page here — the IPO desk, the chapter library, the trade journal tool — is free to read, with no paywall, nothing gated behind payment, and no affiliate links. If any of it has been useful, this is just a way to back the time that goes into writing it, checking the numbers, and keeping it honest.
No perks, no tiers, nothing unlocked for paying more. Just support for the work, if you want to give it. Pay what feels right.